4 6pm SAFE Opioid Prescribing SPEAKERS Charles Argoff, MD, FABPM Bill McCarberg, MD, FABPM Michael Brennan, MD, FACP, FASAM Presenter Disclosure Information The following relationships exist related to this presentation: Dr. Argoff: Advisory Board member for Acorda Therapeutics, Inc., AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, Iroko Pharmaceuticals, LLC, Nektar Therapeutics, Pfizer Inc., Purdue Pharma L.P., and XenoPort, Inc. Consultant for Mallinckrodt Pharmaceuticals, Scirex Corporation, and Zogenix, Inc. Research support from Eli Lilly and Company, Endo Pharmaceuticals Inc., and Forest Laboratories, Inc. Speakers Bureau member for Allergan, Inc., Depomed, Inc., Iroko Pharmaceuticals, LLC, Janssen Pharmaceuticals, Inc., and XenoPort, Inc. Owns stock in Pfizer Inc. Dr. Brennan: Advisory Board member for Depomed, Inc., Insys Therapeutics Inc., Iroko Pharmaceuticals, LLC, Mallinckrodt Pharmaceuticals, Nektar Therapeutics, Purdue Pharma L.P., Teva Pharmaceuticals Industries Ltd., and Zogenix, Inc. Consultant for Purdue Pharma L.P., Teva Pharmaceuticals Industries Ltd., and Zogenix, Inc. Speakers Bureau member for Depomed, Inc., Iroko Pharmaceuticals, LLC, Johnson & Johnson, Purdue Pharma L.P., Teva Pharmaceuticals Industries Ltd., and Zogenix, Inc. Presenter Disclosure Information Dr. McCarberg: Advisory Board member for AstraZeneca Pharmaceuticals LP, Collegium Pharmaceutical, Inc., Depomed, Inc., Inspirion Pharmaceuticals, LLC, Iroko Pharmaceuticals, LLC, Janssen Pharmaceuticals, Inc., Kaléo, Inc., Mallinckrodt Pharmaceuticals, Millennium Laboratories, LLC, Pfizer Inc., Salix Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc., and Zogenix, Inc. Owns stock in BioSpecifics Technologies Corp., Galena Biopharma, Inc., Johnson & Johnson, Nektar Therapeutics, and Protein Design Labs, Inc. Off-Label/Investigational Discussion In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Session IV Talk to Me: Proven Methods to Counsel Your on ER/LA Opioids and Achieve Positive Outcomes Learning Objectives for Session IV Counseling and Caregivers About ER/LA Opioids Upon completion of this module, the participants will be better able to: Implement counseling strategies to ensure patients know to take ER/LA opioids exactly as prescribed Use counseling strategies to explain signs of ER/LA opioid overdose to patients and caregivers Use Patient Counseling Document for ER/LA opioids to: Explain product-specific information Explain how to take and importance of adherence Tell patient and/or caregiver they will receive a Medication Guide from the dispensing pharmacy - Stress importance of reading the Guide and getting answers to any questions they may have from the pharmacist or you Warn patients not to tamper with ER/LA formulation Caution patients about use of other CNS depressants, including alcohol CNS, central nervous system. ER/LA, extended-release and long-acting. /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23,
Counseling and Caregivers (cont d) Instruct patients to tell you about all medications they are taking Warn patients to never abruptly discontinue their ER/LA opioid Caution patients about all adverse effects - Specifically about signs and symptoms of respiratory depression, gastrointestinal obstruction, and allergic reactions - Instruct them on when and how to call you about side effects they experience so that you can work with them to manage Side effects can be reported to FDA at 1-800-FDA-1088 Caution patients to never share their ER/LA opioid with ANYONE Counsel patients about the risk of falls, working with heavy machinery and driving Advise patients to store their medication carefully and dispose of safely when no longer needed - Medication Guides typically include specific disposal information Why is patient and caregiver education so important? Patient Education and Counseling Works! How to Counsel to Use Exactly as Prescribed Utah Department of Health statewide program demonstrated effectiveness of patient education to reduce unintentional deaths from prescription opioids Media campaign Use Only As Directed from May 2008 to May 2009, including: - Television and radio spots - Distribution of opioid prescribing guidelines and copies of print materials (bookmarks, patient information cards, educational posters) Results: In 2008-2009, 14% decrease in unintentional overdose deaths from prescription opioids compared with 2007 THE DOs Tell your patients: Read Medication Guide from dispensing pharmacy Take your medicine exactly as prescribed Store your medicine away from children and in a safe place Flush unused medicine down the toilet Call your health care provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 Johnson EM, et al. Pain Med. 2011;12 suppl 2:S66-S72. /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, How to Counsel to Use Exactly as Prescribed Patient Counseling Document THE DON Ts Tell your patients: Do not give your medicine to others Do not take medicine unless it was prescribed for you Do not stop taking your medicine without talking to your health care provider Do not break, chew, crush, dissolve, or inject your medicine. If you cannot swallow your medicine whole, talk to your health care provider Do not drink alcohol while taking this medicine Patient Counseling Document (PCD) on ER/LA opioid analgesics is a tool designed to facilitate important discussions with patients and: Clearly describes Do s and Don ts related to safe use Gives clinician area to write patient-specific issues and instructions that can be taken by patient from the visit Helps to consolidate informed consent discussion PCD should be provided to and reviewed with patient and/or the caregiver at time of prescribing PCD is available at no charge at www.er-la-opioidrems.com/iwgui/rems/pcd.action /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, ER/LA Analgesics REMS. http://www.er-la-opioidrems.com/iwgui/rems/pcd.action. Accessed May 2,
Patient Counseling Document Case Joan 62-year-old female with severe right hip osteoarthritis Has significant medical issues that prevent her from undergoing total hip replacement Started physical therapy, but stopped because of increase in pain Her pain is significantly affecting her quality of life Unable to take NSAIDs because of previous GI bleed Her PCP initiated a trial of Ultram (tramadol), 50 mg, 1-2 TID, with no reported analgesia This was followed by a 2-week course of Nucynta (tapentadol), 50 mg, 1 PO Q 6 hrs - Reported pain relief for only 3-4 hours, with VRS decreasing from 8 to 5/10 Because of less than optimal duration of effect, PCP decides to initiate a trial of Nucynta ER (tapentadol ER), 100 mg PO Q 12 hrs GI, gastrointestinal; PCP, primary care physician; VRS, verbal rating scale ER/LA Analgesics REMS. http://www.er-la-opioidrems.com/iwgui/rems/pcd.action. Accessed May 2, Ensure Know to Take Opioids ONLY As Prescribed Need to Know About Adherence to Prescribed Opioid Regimen Instructions need to be product-specific:. For instance, since Joan is taking Nucynta ER (tapentadol ER); she should be advised to: - Not crush or chew her medication - Place tablet in mouth and take it with enough water to ensure complete swallowing immediately afterward - Take a dose every 12 hours at same time every day But, if you had prescribed Avinza to Joan, you would advise her to - Swallow capsule intact (whole); never to crush, dissolve or chew the pellets - If she cannot swallow the capsule whole, contents of the Avinza capsule (pellets) can be sprinkled on applesauce and then swallowed without chewing Counsel patients and caregivers ER/LA opioid medication and dosage is based on their individual needs. Doubling up on a dose or taking it sooner than prescribed risks overdose with possible life-threatening consequences Taking more than prescribed constitutes misuse or abuse Missing a dose may result in inadequate pain relief What to do if a dose is missed /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, Explain the Dangers of Combining Opioids With Other Substances Discuss the Dangers of Abruptly Discontinuing Medication Caution patients and caregivers that overdose or death can occur if ER/LA opioids are used with other CNS depressants, including: Sedative-hypnotics: eg, zolpidem (Ambien); triazolam (Halcion); temazepam (Restoril) Anxiolytics: eg, diazepam, clonazepam Illegal drugs: eg, heroin Fatal opioid poisonings have been associated more often with concomitant use of benzodiazepines or alcohol Advise patients to use other CNS depressants, including other opioids, only under instruction of their prescriber Advise patients to tell all their health care providers about all medications they are taking /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, Warn patients to not abruptly discontinue or reduce their ER/LA opioid analgesic and to discuss with you, the opioid prescriber, how to safely taper the dose if they wish to discontinue Abruptly discontinuing an opioid may lead to withdrawal syndrome Stomach cramps, diarrhea, rhinorrhea, sweating, elevated heart rate, increased blood pressure, irritability, dysphoria, hyperalgesia, insomnia /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, 2013; Morgan MM, et al. Br J Pharmacol. 2011;164(4):1322-1334.
Inform of Seriousness of Adverse Events Associated With Opioids Opioid Overdose Caution patients and caregivers that opioids can cause serious side effects that may lead to death Discuss: Signs and symptoms of an overdose, such as: lethargy and somnolence, cognitive impairment Opioid-induced respiratory depression Risk for severe constipation and gastrointestinal obstruction - Emphasize the importance of healthy bowel habits: keeping hydrated, less sedentary Possibility of allergic reactions /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, Fatal overdose is not instantaneous there is usually time for remedial action Naloxone can quickly reverse the effects Both patients and caregivers need to know how to identify opioid overdose, as signs of an overdose are often missed Opioid overdose signs include: Mental depression Hypoventilation (decreased respiration) Reduced bowel motility Miosis (contracted pupils) Green TR, et al. Addiction. 2008;103(6):979-989; Williams RH, et al. Laboratory Med. 2000;31:334-342. Update on Joan Dangers of Sharing Medication: Legal Responsibilities of the Patient Joan returns to office after 1 month Reports better pain relief and improved quality of life Tolerating Nucynta ER (tapentadol ER) 100 mg BID and oxycodone 5 mg, 1-2 per day for breakthrough pain Urine drug toxicology testing (UDT) is completed She reports running out 2 days early and is requesting early refill She states: My daughter hurt her back, so I gave her a couple of my pills. It helped her pain, too. What should you do? In our society, a commonly held belief among patients and caregivers is that sharing prescription medications is not dangerous or a problem because prescription medications are safe. Here s what you should do: Counsel Joan about importance of not giving her medication to or sharing it with others, even her daughter Advise her that drugs prescribed for one patient can have serious or even fatal consequences for another Tell her that sharing prescription medications is illegal Manchikanti L, et al. Pain Physician. 2012;15(3 suppl):s67-s116; SAMHSA (2010). 2009 National Survey on Drug Use and Health. www.samhsa.gov/data/2k9/2k9resultsweb/web/2k9results.htm. Accessed February 22, Storing ER/LA Opioids Safely Disposing of ER/LA Opioids and caregivers must understand importance of storing opioids carefully and protecting them from theft A secure place away from children, family members, household visitors, and pets - eg, a medication safe, which not only deters theft, but also inadvertent use in children, which could be fatal Manchikanti L, et al. Pain Physician. 2012;15(3 suppl):s67-s116; SAMHSA (2010). 2009 National Survey on Drug Use and Health. www.samhsa.gov/data/2k9/2k9resultsweb/web/2k9results.htm. Accessed February 22, Counsel patients to dispose of any ER/LA opioid analgesics that are no longer needed Encourage them to read product-specific disposal information, including the Medication Guide Safe disposal methods include: Dropping off medication at a DEA-designated drop box or take-back program Removing medication from original bottles, mixing with used coffee grounds or kitty litter, and throwing it in the garbage Flushing it down the toilet - Many patients believe that medications should NOT be flushed into the toilet or put into septic or sewer systems. Education can help them understand this is an appropriate disposal DEA, Drug Enforcement Administration. /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, 2013; Practical Pain Management. Opioid Disposal: Dos and Don ts. www.practicalpainmanagement.com/opioid-disposal-dos-don-ts. Accessed January 8,
Learning Objectives for Session V Upon completion of this module, the participants will be better able to: Session V Everything You Always Wanted to Know About ER/LA-Opioids as a Drug Class Assess the differences in opioid metabolism and how these impact appropriate ER/LA prescribing Identify how opioid-drug interactions influence ER/LA opioid prescribing Opioids As A Drug Class General Information ER/LA Opioid Analgesic Products Key Points Federal DEA Controlled Substance Schedules: ER/LA-Opioids are Schedule II 1. ER/LA opioid analgesic products are scheduled under Federal Controlled Substances Act Can be misused and abused Risk for diversion 2. Most serious adverse effect: respiratory depression 3. Most common long-term side effect: constipation 4. Drug-drug interaction profiles: Vary among products Important to recognize and avoid clinically significant interactions 5. Tolerance to sedating and respiratory-depressant effects Clinician and patient understanding of tolerance is fundamental for safe use 6. Adherence to ER/LA opioid dosing instructions is critical Oral formulations must be taken as directed and patients instructed to not tamper with the formulation For transdermal products, external heat, fever, or exertion can increase absorption Sch Description I II III No currently accepted medical use in the U.S.; high potential for abuse High potential for abuse, which may lead to severe psychological or physical dependence Potential for abuse, which may lead to moderate or low physical dependence or high psychological dependence Examples Heroin, LSD, marijuana, peyote, methaqualone, Ecstasy Hydromorphone, methadone, meperidine, oxycodone, fentanyl, morphine, opium, and codeine, amphetamine, methamphetamine, methylphenidate, hydrocodone combination products (as of 10/6/14) Products containing 90 mg codeine per dose, buprenorphine, benzphetamine, phendimetrazine, ketamine, anabolic steroids IV Low potential for abuse Alprazolam, carisoprodol, clonazepm, clorazepate, diazepam, lorazepam, midazolam, temazepam, tramadol (as of 2014), triazolam V Low potential for abuse Cough preparations containing 200 mg codeine per 100 ml or per 100 g, ezogabine DEA Diversion Control. Available at www.deadiversion.usdoj.gov/schedules/index.htm. Accessed Aug, 2014 Neurobiology of Opioids Opioid Receptors and Analgesia Opioid receptors are ubiquitous Found throughout CNS and within GI tract Accounts for their numerous effects, including potent analgesia, sedation, and reduced GI motility Are G-coupled receptors Both endogenous and exogenous opioids exert their effect by acting as ligands on these receptors Analgesic effects likely mediated through mu opioid receptors Highly concentrated in the outer laminae of spine dorsal horn Two areas of brainstem rostral ventromedial medulla (RVM) and periaqueductal gray (PAG) area. Schäfer M. Opioids in Pain Medicine. In: Kopf A, et al, eds. Guide to Pain Management in Low-Resource Settings. Washington, DC: International Association for the Study of Pain; 2010. http://www.iasppain.org/am/template.cfm?section=home&template=/cm/contentdisplay.cfm&contentid=12166. Accessed March 2,
Respiratory Depression Constipation Most common serious adverse effect Can be immediately life-threatening Factors that may increase risk for respiratory depression include: Sleep apnea or snoring Morbid obesity Older age Opioid naïve Concomitant use of other sedating drugs Smoking Most common long-term side effect Activation of GI peripheral opioid receptors decreases GI motility and increases fluid absorption Nausea and vomiting may develop as primary AE or over time as a sign of chronic constipation Constipation should be anticipated and managed prophylactically eg, increase fiber and water intake OTC agents include bulking, lubricants, stimulants Prescription agents include stimulants, chloride ion (CIC-2) activators (eg, lubiprostone) and opiate antagonists (eg, methylnaltrexone, naloxegol) Opioid rotation may be warranted AE, adverse event. Schäfer M. Opioids in Pain Medicine. In: Kopf A, et al, eds. Guide to Pain Management in Low-Resource Settings. Washington, DC: International Association for the Study of Pain; 2010. http://www.iasppain.org/am/template.cfm?section=home&template=/cm/contentdisplay.cfm&contentid=12166. Accessed March 2, Schäfer M. Opioids in Pain Medicine. In: Kopf A, et al, eds. Guide to Pain Management in Low-Resource Settings. Washington, DC: International Association for the Study of Pain; 2010. http://www.iasp pain.org/am/template.cfm?section=home&template=/cm/contentdisplay.cfm&contentid=12166. Accessed March 2, 2013; National Comprehensive Cancer Network Guidelines Version 1.2012. Adult Cancer Pain. http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed February 27, 2013; Chou R, et al. J Pain. 2009;10(2):113-130. Drug-Drug (DDI) Are Common and Vary Among Opioids CNS Depressants May Potentiate Opioid Effects Underlying mechanisms Pharmacodynamics (pd) - Pharmacological effects Pharmacokinetics (pk) - Drug absorption, metabolism and clearance DDI may enhance or inhibit either pk or pd, thus altering intended and/or precipitating unintended effects Pharmacodynamic (PD) interaction Concomitant use increases risk of: Respiratory depression Hypotension Profound sedation, coma Management includes reducing the initial dose of both opioid and CNS depressant Examples of CNS depressants Sedatives Hypnotics Tricyclic Antidepressants general anesthetics antiemetics phenothiazines alcohol marijuana other tranquilizers /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, Alcohol and ER/LA Opioids Pharmacodynamic (PD) MAOIs and ER/LA Opioids PD With some ER/LA opioid formulations, rapid release of opioid may occur when exposed to alcohol Known as dose dump Can result in fatal toxicity Alcohol may increase opioid drug levels and predispose to adverse effects, including overdose How to manage: Counsel patients to not consume alcohol when taking opioids See product-specific warnings Concomitant use of monoamine oxidase inhibitors (MAOIs) and opioids may increase risk of respiratory depression May also cause serotonin syndrome Serotonin Syndrome Symptoms Agitation or restlessness Diarrhea Fast heart beat and high blood pressure Hallucinations Increased body temperature Loss of coordination Nausea Overactive reflexes Rapid changes in blood pressure Vomiting Spontaneous or induced clonus How to Manage Maintain hemodynamics Reduce/Discontinue offending agent U.S. Food and Drug Administration. FDA Alert [7/2005]: Alcohol-Palladone Interaction. /Drugs/DrugSafety/PostmarketDrugSafetyInformationforandProviders/ ucm129288.htm. Accessed March 3, /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, 2013; Gillman PK. Br J Anaesth. 2005;95(4):434-441.
Opioids and Other Drug Opioids and Other Drug (cont d) Opioids can induce release of antidiuretic hormone (ADH) Can reduce efficacy of diuretics Avoid co-administration of opioids with partial agonists or mixed agonist/antagonist analgesics May reduce the analgesic effect and can precipitate withdrawal symptoms - Buprenorphine (Butrans) - Nalbuphine (Nubain) - Butorphanol (Stadol) Skeletal Muscle Relaxants Opioids may enhance neuromuscular blocking action and increase risk of respiratory depression Anticholinergics Increased risk of urinary retention Increased risk of severe constipation, which may lead to paralytic ileus Reisine T, et al. In: Goodman & Gilman s: The Pharmacological Basis of Therapeutics (9th ed). McGraw-Hill; 1996. 521-555; FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics. /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, Summary of Opioid-Drug Opioids and QTc Prolongation Concomitant Use of ER/LA Opioids With: Other CNS depressants (alcohol, sedatives, hypnotics, tranquilizers, tricyclic antidepressants) Partial agonists, mixed agonist/antagonist analgesics (buprenorphine, pentazocine, nalbuphine, butorphanol) Skeletal muscle relaxants Anticholinergic agents Potential Effects Increased risk of respiratory depression, hypotension, profound sedation, or coma; reduce the initial dose of 1 or both agents May reduce analgesic effect or precipitate withdrawal symptoms; avoid concurrent use Increased respiratory depression Increased risk of urinary retention and severe constipation, which may lead to paralytic ileus Methadone and buprenorphine can prolong QTc interval in some patients Dose-related incidence in patients on long-term methadone maintenance 9% at a dose >300 mg/d 83% at a dose >600 mg/d Management: Monitor EKG Consider alternative drugs should any abnormality develop /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed August 2014. ; Reddy S, et al. J Palliat Med. 2010;13(1):33-38. Cytochrome P450 Enzymes Opioids and CYP450 Account for almost 50% of overall elimination of commonly used drugs, including: Statins SSRIs Calcium channel blockers Benzodiazepines Beta Blockers Opioids Warfarin Pharmacokinetic drug-drug interactions can cause higher or lower blood levels of opioid than expected and result in: Excess opioid effects (including fatal toxicity) Loss of analgesia Misinterpretation of drug tests CYP450 drug-drug interactions often clinically relevant SSRI, selective serotonin reuptake inhibitor. Indiana University School of Medicine. Drug. http://medicine.iupui.edu/flockhart/table.htm. Accessed November 6, 2012; Wilkinson GR. N Engl J Med. 2005;352(21):2211 2221. Overholser BR, et al. Am J Manag Care. 2011;17 suppl 1:S276-S287.
ER/LA Opioids and CYP450 Enzyme Peter s Current Medication Regimen Metabolism of several commonly used opioids occurs through enzyme CYP3A4, but CYP2D6 is also important 3A4 is a potent inactivation enzyme 2D6 is an activating enzyme Inhibition Can increasedrug plasma levels, resulting in greater drug-related effects Stimulation Can decreasedrug plasma levels and decrease drug-related effects However, if an agent is a pro-drug, an inhibitor can decrease drug effects, while an inducer increases the rapidity with which the active compound enters the bloodstream Refer to product-specific information for specific opioid-ddis before prescribing Returns to your office complaining of serious foot fungus. Current medications: Oxycodone CR tablets 40 mg every 12 hours Hydrocodone/acetaminophen 5/500 8/day for breakthrough pain Gabapentin 300 mg/2 tablets TID Zolpidem 10 mg/hs When considering a medication to treat the fungus, should you be concerned about possible drug-drug interactions? YES many commonly used antifungals have known CYP450 interactions Overholser BR, et al. Am J Manag Care. 2011;17 suppl 1:S276-S287. Overview of Opioid Metabolism With Other Agents and Substances Active Components Morphine Metabolism (CYP450) Not significantly metabolized by CYP450 Agent Concomitant Use With: Potential Effect on Opioid Levels and Other Effects Oxymorphone Tapentadol Hydromorphone Oxycodone Hydrocodone Hydrocodone + Acetaminophen Tramadol Codeine Fentanyl Methadone Oxycodone + Acetaminophen www.accessdata.fda.gov. Not significantly metabolized by CYP450 Not significantly metabolized by CYP450 Not significantly metabolized by CYP450 2D6, 3A4 3A4 2D6, 3A4 2D6, 3A4 2D6 3A4 3A4, 2B6, 2D6, 2C9, 2C19 2D6, 3A4 Avinza (morphine sulfate ER capsule) Butrans (buprenorphine transdermal system) Dolophine* (methadone HCl tablets) Alcohol PGP Inhibitors (quinidine) CYP3A4 inhibitors CYP3A4 inducers Benzodiazepines Class IA and III antiarrythmics, other potentially arrhythmogenic agent CYP450 inducers CYP450 inhibitors Anti-retroviral agents Benzodiazepines Potentially arrhythmogenic agents (potentially fatal dose) Respiratory depression QTc prolongation and torsade de pointe risk Mixed effects on levels Respiratory depression QTc prolongation and torsade de pointe risk * Pharmacokinetic drug-drug interactions with methadone are complex. Refer to package insert for additional information. /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, With Other Agents and Substances With Other Agents and Substances Agent Duragesic (fentanyl transdermal system) Concomitant Use With: CYP3A4 inhibitors CYP3A4 inducers Potential Effects on Opioid Levels and Other Effects Agent Nucynta ER (tapentadol HCl ER tablets) Concomitant Use With: Alcohol MAOIs Potential Effects on Opioid Levels and Other Effects (potentially fatal dose) Contraindicated in patients taking MAOIs Embeda (morphine sulfate ER-naltrexone capsules) Alcohol PGP Inhibitors (quinidine) (potentially fatal dose) Opana ER (oxymorphone HCl ER tablets) Alcohol (potentially fatal dose) Exalgo (hydromorphone HCl ER tablets) Hysingla ER (hydrocodone bitartrate ER tablets) Kadian (morphine sulfate ER capsules) MS Contin (morphine sulfate CR tablets) None CYP3A4 inhibitors CYP3A4 inducers Alcohol PGP Inhibitors (quinidine) PGP Inhibitors (quinidine) (potentially fatal dose) OxyContin (oxycodone HCl CR tablets) Targiniq ER (oxycodone HCl / naloxone HCl) Zohydro ER (hydrocodone bitartrate ER capsules) CYP3A4 inhibitors CYP3A4 inducers 2D6 inhibitors 2D6 inducer CYP3A4 inhibitors CYP3A4 inducers CYP3A4 inhibitors CYP3A4 inducers Increased effect /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23,
Drug Between Methadone or Buprenorphine and Select Medications Tolerance to Sedating and Respiratory Depressant Side Effects Medication Methadone Buprenorphine AZT Increase in AZT concentrations; possible No clinical significant interaction AZT toxicity Lopinavir/Ritonavir Opiate withdrawal may occur No clinically significant interaction Rifampin Opiate withdrawal may occur Opiate withdrawal may occur Fluconazole Increased methadone plasma concentrations Ciprofloxacin Increased methadone plasma concentrations Sertraline No associated adverse drug interactions No clinically significant interaction Duloxetine Potentially increases duloxetine exposure Dextromethorphan Associated with delirium Aripiprazole No clinically significant interaciton No clinically significant interaction Carbamazepine Associated with opiate withdrawal Not studied Opioid-naïve patients no prior opioid exposure Especially prone to most serious adverse effects of opioids Tolerance to sedating and respiratory-depressant effects critical to safe use of certain opioid products, dosages, and strengths Opioid-tolerant patient: at least 1 wk of tx = 60 mg morphine or equivalent/day must be opioid tolerant before using any strength of transdermal fentanyl or ER hydromorphone With other ER/LA products, patients must be opioid tolerant before using certain strengths or certain daily doses Methylphenidate No clinically significant interaction No clinically significant interaction Diphenhydramine May have synergistic depressant effect Adapted from McCance-Katz EF, et al. Am J Addict. 2010;19(1):4-16. /downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf. Accessed February 23, Other Important Opioid Safety Issues Oral formulations of ER/LA opioids must be taken as directed. Instruct patients to not tamper with the formulation: - Swallow tablets whole - Swallow capsules whole/intact - If necessary, pellets from some capsules can be sprinkled on applesauce and swallowed without chewing For transdermal products, instruct patients on proper and safe use External heat, fever, and exertion can increase absorption of the opioid, leading to fatal overdose Transdermal products with metal foil backings are not safe for use in MRIs Session VI Getting the Most Clinical Insights from Specific ER/LA Product Information Sources Learning Objectives for Session VI Prescribers Must Be Knowledgeable Upon completion of this module, the participants will be better able to: Differentiate the prescribing information among available ER/LA opioids Identify ER/LA opioids and dosages indicated for opioid-tolerant patients only Before prescribing an opioid, each clinician needs to be knowledgeable about specific characteristics of each available ER/LA opioid, including: Drug substance Formulation Strength Dosing interval Key instructions reserve for use in patients for whom alternative treatment options (eg, non-opioid analgesics or immediaterelease opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain
Prescribing Information The FDA Definition of Opioid Tolerance For detailed information, prescribers can refer to the prescribing information available online: DailyMed at www.dailymed.nlm.nih.gov /drugsatfda Opioid naïve vs opioid tolerant are considered opioid tolerant if they are taking, for 1 week or longer, at least: Oral morphine 60 mg daily Transdermal fentanyl 25 mcg/h Oral oxycodone 30 mg daily Oral hydromorphone 8 mg daily Oral oxymorphone 25 mg daily Equianalgesic daily dose of another opioid Certain ER/LA opioid medications should ONLY be initiated in patients who have become opioid tolerant as a result of ongoing therapy. Avinza Morphine Sulfate ER Butrans Buprenorphine Avinza PGP, P-glycoprotein Morphine Sulfate ER Capsules, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg, and 120 mg Once a day Initial dose in opioid non-tolerant patients: 30 mg Maximum daily dose: 1600 mg Initial dose in opioid non-tolerant patients: 30 mg Titrate using minimum of 3-day intervals (4-day intervals in opioid nontolerant patients) Instruct patient: - Swallow capsule whole (do not chew, crush, or dissolve) - If unable to swallow, capsule can be opened and pellets sprinkled on applesauce for patients Avoid alcoholic beverages or medications containing alcohol; may result in dose dump and absorption of potentially fatal dose of morphine PGP inhibitors (eg, quinidine) may increase absorption/exposure of morphine sulfate by approximately 2x Use 90 mg and 120 mg capsules in opioid-tolerant patients ONLY Butrans Buprenorphine Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, and 20 mcg/hr One transdermal system every 7 days Initial dose: 5 mcg/hr. Maximum dose: 20 mcg/hrdue to risk of QTc prolongation When used as first opioid analgesic initiate treatment with 5 mcg/hr If prior total daily dose of opioid < 30 mg oral morphine equivalents per day, initiate treatment with 5 mcg/hr dose If prior total daily dose of opioid between 30 mg to 80 mg of oral morphine equivalents, taper patient s opioid for up to 7 days to no more than 30 mg of morphine equivalents, then initiate with 10 mcg/hr dose The minimum titration interval is 72 hours Instruct patient Apply only to sites indicated in full prescribing information Apply to intact/non-irritated skin Skin may be prepped by clipping hair, washing site with water only Rotate site of application; allow a minimum of 3 weeks before reapplying to same site Do not cut Avoid exposure to heat Dispose of used/unused patches by folding the adhesive side together and flushing down toilet Butrans Buprenorphine (cont d) Dolophine Methadone Hydrochloride Butrans Drug-Specific Safety Concerns Buprenorphine Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr CYP3A4 inhibitors may increase buprenorphine levels CYP3A4 inducers may decrease buprenorphine levels Benzodiazepines may increase respiratory depression Class IA and III antiarrythmics, other potentially arrhythmogenic agents, may increase risk for QTc prolongation and torsade de pointe Use 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr transdermal systems in opioid-tolerant patients ONLY QTc prolongation and torsade de pointe Hepatotoxicity Application site skin reactions Torsade de pointe (TdP) a form of polymorphic ventricular tachycardia that may result in syncope or cardiac arrest. Dolophine Methadone Hydrochloride Tablets, 5 mg and 10 mg Every 8 to 12 hours Initial dose in opioid non-tolerant patients: 2.5 mg to 10 mg slowly titrated to effect Conversion of opioid-tolerant patients using equianalgesic tables can result in overdose and death; use low doses according to table in full prescribing information (PI) High interpatient variability in absorption, metabolism, and relative analgesic potency Opioid detoxification or maintenance treatment shall only be provided in a federally certified opioid (addiction) treatment program Complex pharmacokinetic drug-drug interactions with methadone CYP450 inducers may increase methadone levels CYP450 inhibitors may decrease methadone levels Antiretroviral agents have mixed effects on methadone levels Potentially arrhythmogenic agents may increase risk for QTc prolongation and torsade de pointe Benzodiazepines may increase respiratory depression
Dolophine Methadone Hydrochloride (cont d) Duragesic Fentanyl Transdermal System Dolophine Product-Specific Safety Concerns Relative Potency to Oral Morphine Methadone Hydrochloride Tablets, 5 mg and 10 mg Refer to full prescribing information QTc prolongation and torsade de pointe Peak respiratory depression occurs later and persists longer than analgesic effect Clearance may increase during pregnancy False-positive urine drug screens possible Varies depending on patient s prior opioid experience Duragesic Fentanyl Transdermal System, 12, 25, 50, 75, and 100 mcg/hr Every 72 hours (3 days) Use product-specific information in the full prescribing information for dose conversion from prior opioid Use 50% of the dose in mild or moderate hepatic or renal impairment; avoid use in severe hepatic or renal impairment Titrate generally using no less than 72-hour intervals; some patients may require 48 hour titration if adequate analgesia not achieved at 72 hour dose Instruct patient: - Apply to intact/non-irritated/non-irradiated skin on a flat surface - Skin may be prepped by clipping hair, washing site with water only - Rotate site of application - Do not cut - Avoid exposure to heat - Avoid accidental contact when holding or caring for children - Dispose used/unused patches by folding the adhesive side together and flushing down the toilet Specific contraindications: who are not opioid-tolerant Management of acute or intermittent pain, or in patients who require opioid analgesia for a short period of time Management of postoperative pain, including use after outpatient or day surgery Management of mild pain Duragesic Fentanyl Transdermal System (cont d) Embeda Morphine Sulfate ER-Naltrexone Duragesic Product-Specific Safety Concerns Relative Potency to Oral Morphine Fentanyl Transdermal System, 12, 25, 50, 75, and 100 mcg/hr CYP3A4 inhibitors may increase fentanyl drug levels and exposure CYP3A4 inducers may decrease fentanyl drug levels and exposure Discontinuation of a concomitantly used CYP3A4 inducer may result in an increase in fentanyl plasma concentration Indicated for use in opioid-tolerant patients ONLY Accidental exposure due to secondary exposure to unwashed/unclothed application site Increased drug exposure with increased core body temperature or fever Bradycardia Application site skin reactions See full prescribing information for conversion recommendations from prior opioid Embeda Morphine Sulfate ER-Naltrexone Capsules, 20 mg/0.8 mg, 30 mg/1.2 mg, 50 mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, and 100 mg/4 mg Once a day or every 12 hours Initial dose as first opioid: 20 mg/0.8 mg Titrate using 1-2 day intervals Swallow capsules whole (do not chew, crush, or dissolve) Instruct patient: - Crushing or chewing will release morphine, possibly resulting in fatal overdose, and naltrexone, possibly resulting in withdrawal symptoms - If unable to swallow capsule whole, can open capsule and sprinkle pellets on applesauce; use immediately Alcoholic beverages or medications containing alcohol may result in the rapid release and absorption of a potentially fatal dose of morphine GP inhibitors (eg, quinidine) may increase the absorption/exposure of morphine sulfate by approximately 2-fold Use 100 mg/4mg capsule in opioid-tolerant patients ONLY Exalgo Hydromorphone Hydrochloride Hysingla ER Hydrocodone Bitartrate Exalgo Drug-Specific Adverse Reactions Relative Potency to Oral Morphine Hydromorphone Hydrochloride Extended-Release Tablets, 8 mg, 12 mg, 16 mg, and 32 mg Once a day Titrate using a minimum of 3- to 4-day intervals Use conversion ratios in the full prescribing information Start patients with moderate hepatic impairment on 25% of the dose that would be prescribed for a patient with normal hepatic function Start patients with moderate renal impairment on 50%, and patients with severe renal impairment on 25% of the dose that would be prescribed for a patient with normal renal function Do not use in patients with sulfa allergy Instruct patient to swallow tablets whole - DO NOT chew, crush, or dissolve None Use in opioid-tolerant patients ONLY Allergic manifestations to sulfa component Approximately 5:1 oral morphine to hydromorphone oral dose ratio, use conversion recommendations in the full prescribing information Hysingla ER Relative Potency to Oral Morphine Abuse Deterrence Hydrocodone Bitartrate Extended-Release Tablets, 20, 30, 40, 60, 80, 100 mg Once a day (every 24 hours) Titrate in increments of 10 mg to 20 mg every 3-5 days In patients who are not opioid tolerant, initiate therapy with 20 mg QTc prolongation has been observed with daily doses of 160 mg Hepatic impairment: use half the initial dose Renal impairment: use half the initial dose Instruct patients to swallow tablets whole Use caution in patients who have difficulty swallowing or have underlying GI disorders that may predispose them to obstruction Initiation of CYP3A4 inhibitors or discontinuation of CYP3A4 inducers can result in fatal overdose of hydrocodone Doses equal to or greater than 80 mg are for use in opioid tolerant patients only Discontinue all other around-the-clock opioids when Hysingla ER is initiated; use conversion recommendations in the full prescribing information This product is formulated with physicochemical properties intended to make the tablet more difficult to manipulate for misuse and abuse.
Kadian Morphine Sulfate MS Contin Morphine Sulfate Kadian Morphine Sulfate Extended-Release Capsules, 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 130 mg, 150 mg, and 200 mg MS Contin Morphine Sulfate Controlled-Release Tablets, 15 mg, 30 mg, 60 mg, 100 mg, and 200 mg Once a day or every 12 hours Titrate using a minimum of 2-day intervals Do not use as first/initial opioid (see PI) Instruct patient: - Swallow capsules whole DO NOT chew, crush, or dissolve - If unable to swallow capsule whole, can open capsule and sprinkle pellets on applesauce; use immediately Do not use with alcoholic beverages or medications containing alcohol as may result in the rapid release and absorption of a potentially fatal dose of morphine PGP inhibitors (eg, quinidine) may increase the absorption/exposure of morphine sulfate by approximately 2-fold Kadian 100-mg, 130 mg, 150 mg and 200-mg capsules are for use in opioidtolerant patients ONLY Every 8 hours or every 12 hours Titrate using a minimum of 2-day intervals Do not use as first/initial opioid (see PI) Instruct patient to swallow tablets whole - Do NOT chew, crush, or dissolve PGP inhibitors (eg, quinidine) may increase the absorption/exposure of morphine sulfate by approximately 2-fold Use MS Contin 100-mg and 200-mg tablet strengths in opioid-tolerant patients ONLY Nucynta ER Tapentadol Nucynta ER Tapentadol (cont d) Nucynta ER Tapentadol Extended-Release Tablets, 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg Nucynta ER Tapentadol Extended-Release Tablets, 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg Every 12 hours Use 50 mg every 12 hours as initial dose in opioid non-tolerant patients Titrate by 50 mg increments using a minimum of 3-day intervals Maximum total daily dose is 500 mg Dose once daily in moderate hepatic impairment with 100 mg per day maximum Avoid use in severe hepatic and renal impairment Instruct patient : - Swallow tablets whole Do not chew, crush, or dissolve - Take 1 tablet at a time and with enough water to ensure complete swallowing immediately after placing in the mouth Do not use with alcoholic beverages or medications containing alcohol as may result in the rapid release and absorption of a potentially fatal dose of tapentadol Contraindicated in patients taking MAOIs Product-Specific Safety Concerns Relative Potency to Other Oral Opioids No product-specific considerations Risk of serotonin syndrome Angioedema Equipotency to oral morphine not established Studies leading to its FDA approval use a dose ratio of 5:1 of Tapentadol ER to Oxycodone CR Opana ER Oxymorphone Hydrochloride OxyContin Oxycodone Hydrochloride Opana ER Use in Opioid- Tolerant Relative Potency to Oral Morphine Oxymorphone Hydrochloride Extended-Release Tablets, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 40 mg Every-12-hours dosing; some benefit from asymmetric (different dose given in AM than PM) dosing Use 5 mg every 12 hours as initial dose in opioid non-tolerant patients and patients with mild hepatic impairment and renal impairment (creatinine clearance <50 ml/min) and in patients over 65 years of age Titrate using 3-7-day intervals Contraindicated in moderate and severe hepatic impairment Instruct patient: Swallow tablets whole (do not chew, crush, or dissolve) Take 1 tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth Use with caution in patients who have difficulty swallowing or have underlying GI disorders that may predispose them to obstruction Do not use with alcoholic beverages or medications containing alcohol as may result in absorption of a potentially fatal dose of oxymorphone No product specific considerations Approximately 3:1 oral morphine to oxymorphone oral dose ratio OxyContin Oxycodone Hydrochloride Controlled-Release Tablets, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, and 80 mg Every 12 hours Opioid-naïve patients: initiate treatment with 10 mg every 12 hours Titrate using a minimum of 1- to 2-day intervals Hepatic impairment: start with one-third to one-half usual dosage Renal impairment (creatinine clearance <60 ml/min): start with one-half usual dosage Consider use of other analgesics in patients who have difficulty swallowing or have underlying GI disorders that may predispose them to obstruction Instruct patient: - Swallow tablets whole DO NOT chew, crush, or dissolve - Take 1 tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth CYP3A4 inhibitors may increase oxycodone exposure CYP3A4 inducers may decrease oxycodone exposure
OxyContin Oxycodone Hydrochloride (cont d) Targiniq ER Oxycodone HCl / Naloxone HCl OxyContin Oxycodone Hydrochloride Controlled-Release Tablets, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, and 80 mg Targiniq ER Oxycodone Hydrochloride / Naloxone Hydrochloride Extended-Release Tablets, 10 mg/5 mg, 20 mg/10 mg, and 40 mg/20 mg Product-Specific Safety Concerns Relative Potency to Oral Morphine New as of 4/16/2013 Single dose greater than 40 mg or total daily dose greater than 80 mg is for use in opioid-tolerant patients ONLY Choking, gagging, regurgitation, tablets stuck in the throat, difficulty swallowing the tablet Contraindicated in patients with GI obstruction Approximately 2:1 oral morphine to oxycodone oral dose ratio This product has abuse-deterrent properties. The tablet is more difficult to crush, break, or dissolve. It forms a viscous hydrogel and cannot be easily prepared for injection. Every 12 hours Opioid-naïve patients: initiate treatment with 10 mg/5 mg every 12 hours Titrate using a minimum of 1- to 2-day intervals Do not exceed 80 mg/40 mg total daily dose Hepatic impairment: contraindicated in moderate and severe hepatic impairment. In mild hepatic impairment, start with one-third to one-half usual dosage Renal impairment (creatinine clearance <60 ml/min): start with one-half usual dosage Instruct patient: - Swallow tablets whole DO NOT chew, crush, split or dissolve as this will release oxycodone possibly resulting in fatal overdose, and naloxone, possibly resulting in withdrawal symptoms - Take 1 tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth CYP3A4 inhibitors may increase oxycodone exposure CYP3A4 inducers may decrease oxycodone exposure Targiniq ER Oxycodone HCl / Naloxone HCl Zohydro ER Hydrocodone Bitartrate Targiniq ER Oxycodone Hydrochloride / Naloxone Hydrochloride Extended-Release Tablets, 10 mg/5 mg, 20 mg/10 mg, and 40 mg/20 mg Zohydro ER Hydrocodone Bitartrate Extended-release capsules 10 mg, 15 mg, 20 mg, 30 mg, 40 mg and 50 mg Use in opioid-tolerant patients Product-specific safety concerns Relative potency to oral morphine Singe dose greater than 40 mg/20 mg or total daily dose of 80 mg/40 mg are for use in opioid-tolerant patients only Contraindicated in moderate and severe hepatic impairment. See individual product information for conversion recommendations from prior opioid patients Every 12 hours Opioid-naïve patients: initiate treatment with 10 mg every 12 hours Titrate using 3- to 7-day intervals Renal impairment (creatinine clearance <60 ml/min): start with a low dose Instruct patient: - Swallow capsules whole DO NOT chew, crush, or dissolve CYP3A4 inhibitors may increase hydrocodone exposure CYP3A4 inducers may decrease hydrocodone exposure Single dose greater than 40 mg or total daily dose greater than 80 mg are for use in opioid-tolerant patients only Relative Potency to Oral Morphine Approximately 1.5:1 oral morphine to hydrocodone oral dose ratio